OncoMatch/Clinical Trials/NCT07151040
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Is NCT07151040 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies TH9619 for solid tumor.
Treatment: TH9619 — This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Colorectal Cancer
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Carcinoma
Gastric Cancer
Disease stage
Metastatic disease required
Prior therapy
Must have received: cytotoxic chemotherapy — metastatic/unresectable
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07151040 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received cytotoxic chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify